# Isoproterenol infusion enhances composition and function of G-CSF mobilized allogeneic peripheral blood hematopoietic cell grafts

**Authors:** Helena Batatinha, Grace M. Niemiro, Nicole A. Peña, Giovannah A. Hoskin, Tiffany M. Zúñiga, Kyle A. Smith, Forrest L. Baker, Douglass M. Diak, Preteesh L. Mylabathula, Timothy M. Kistner, Michael D. Seckeler, Emmanuel Katsanis, Richard J. Simpson

PMC · DOI: 10.1186/s13287-025-04725-4 · Stem Cell Research & Therapy · 2025-11-05

## TL;DR

Adding isoproterenol to G-CSF improves the quality of blood cell grafts used in transplants, reducing harmful side effects and boosting cancer-fighting effects.

## Contribution

This study shows that isoproterenol enhances graft composition and outcomes in allogeneic hematopoietic cell transplantation.

## Key findings

- Isoproterenol increased NK and TCR-γδ T cells while reducing naïve CD4 and CD8 T cells in mobilized grafts.
- G-CSF plus isoproterenol grafts showed improved anti-tumor activity and reduced GvHD in mice.
- Mice receiving G-CSF plus isoproterenol grafts had 42% survival at day 40 compared to 21% with G-CSF alone.

## Abstract

Graft-versus-host disease (GvHD) and relapse remain critical challenges in allogeneic hematopoietic cell transplantation (alloHCT). Graft composition is pivotal, with naïve T cells increasing GvHD risk and NK cells improving graft-versus-leukemia (GvL) effects. Acute beta-adrenergic receptor activation mobilizes effector lymphocytes, favorably altering circulating immune cell composition. This study investigated whether infusing the non-selective beta-agonist isoproterenol (ISO) after granulocyte colony-stimulating factor (G-CSF) mobilization enhances peripheral blood hematopoietic cell (PBHC) graft composition and outcomes.

Ten healthy volunteers received a 20-minute ISO infusion before and after five days of G-CSF hematopoietic cell mobilization. G-CSF and G-CSF + ISO mobilized PBHCs were phenotyped and assessed for in vitro cytotoxicity. NSG leukemia-bearing mice were injected with G-CSF or G-CSF + ISO mobilized PBHCs and monitored for GvHD, tumor burden, and overall survival.

After G-CSF mobilization, ISO increased the numbers of CD34 + cells in the blood and favorably altered graft composition, increasing NK (9.5% to 27.9%) and TCR-γδ T cells (5.0% to 7.5%) while reducing naïve CD4 (18.1% to 11.2%) and CD8 (8.9% to 5.8%) T cells. Effector lymphocytes mobilized by G-CSF + ISO, particularly effector-memory CD8 + T-cells and NK-cells, exhibited upregulated genes and enriched gene sets linked to anti-tumor activity (e.g. NKG7, GZMB, NK cells cytotoxicity). This resulted in an 8-fold increase in cytolysis against the K562 leukemia cell line compared to PBHC mobilized by G-CSF only. In xenogeneic mice, G-CSF + ISO grafts reduced GvHD, extended survival, and improved GvL effects, with 42% of mice surviving at day 40 compared to 21% for G-CSF grafts.

ISO infusion post-G-CSF mobilization favorably enhances graft composition, mitigates GvHD, prolongs survival, and augments GvL effects. Our findings suggest that acute systemic beta-adrenergic receptor activation could be a valuable strategy to enhance outcomes in alloHCT.

The online version contains supplementary material available at 10.1186/s13287-025-04725-4.

## Linked entities

- **Genes:** NKG7 (natural killer cell granule protein 7) [NCBI Gene 4818], GZMB (granzyme B) [NCBI Gene 3002]
- **Chemicals:** isoproterenol (PubChem CID 3779)
- **Diseases:** Graft-versus-host disease (MONDO:0013730), leukemia (MONDO:0004355)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Nkg7 (natural killer cell group 7 sequence) [NCBI Gene 72310] {aka 2500004F03Rik}, Csf3 (colony stimulating factor 3 (granulocyte)) [NCBI Gene 12985] {aka Csfg, G-CSF, MGI-IG}, Gzmb (granzyme B) [NCBI Gene 14939] {aka CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB}, Cd34 (CD34 antigen) [NCBI Gene 12490], Trav6-3 (T cell receptor alpha variable 6-3) [NCBI Gene 328483] {aka Gm13948, Gm193, Gm4, TCR}
- **Diseases:** cytotoxicity (MESH:D064420), NSG leukemia (MESH:D007938), tumor (MESH:D009369), Graft-versus-host disease (MESH:D006086)
- **Chemicals:** ISO (MESH:D007545)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** K562 — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_0004)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12587703/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12587703/full.md

---
Source: https://tomesphere.com/paper/PMC12587703